Michael Zile to Cost-Benefit Analysis
This is a "connection" page, showing publications Michael Zile has written about Cost-Benefit Analysis.
Connection Strength
0.212
-
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord. 2021 03 26; 21(1):155.
Score: 0.161
-
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. 2016 09 01; 1(6):666-72.
Score: 0.029
-
In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol. 2012 Oct 15; 110(8):1150-5.
Score: 0.022